This site is intended only for healthcare professionals residing in Malaysia

Search

Menu

Close

Log Out Our medicinesTherapy AreaExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usPfizer Medical Information

Menu

Close

HomeAbout DosingEfficacySafety and tolerabilityImportant safety information InteractionsFertility, Pregnancy and lactationUndesirable effectsGuidelinesResourcesProduct InformationEventsMaterialsVideos
DosingTazocin® must be given  by slow intravenous infusion (e.g., over 20-30 minutes) or slow intravenous injection (over at least 3-5 minutes).

Duration of therapy

The duration of therapy should be guided by the severity of the infection and the patient's clinical and bacteriological progress.

Adults and children aged 12 years and older

In general, the recommended total daily dosage is 12 g of piperacillin/1.5 g of tazobactam given in divided doses every 8 hours. The total daily dose depends on the severity and localization of the infection and can vary from 2.25 g to 4.5 g of piperacillin/tazobactam administration every 6 or 8 hours.

For bacterial infections in neutropenic patients, the recommended dose is 4 g piperacillin/0.5 g tazobactam administered every 6 hours in combination with an aminoglycoside.

Children under the age of 12 years

For neutropenic children with fever suspected to be due to bacterial infections,* the recommended dose is 80 mg piperacillin/10 mg tazobactam per kg body weight, administered every 6 hours (in combination with an aminoglycoside).

For children weighing over 50 kg, follow the adult dosing, in combination with the appropriate dose of an aminoglycoside.

* Not to exceed the maximum 4 g/0.5 g per dose over 30 minutes.

TitleThe safety and efficacy of Tazocin in children 0–2 years of age has not been established. No data from controlled clinical studies are available.

Special populations

Renal impairment

The intravenous dose should be adjusted to the degree of actual renal impairment as follows (each patient must be monitored closely for signs of substance toxicity; medicinal product dose and interval should be adjusted accordingly):

In adults and children 12 years and older with creatinine clearances:

  • >40 ml/min, no dose adjustment is necessary
  • 20–40 ml/min, the maximum dose suggested is 4 g/0.5 g every 8 hours
  • <20 ml/min, the maximum dose suggested is 4 g/0.5 g every 12 hours

In children 2–12 years of age with creatinine clearances:

  • >50 ml/min, no dose adjustment is necessary
  • ≤50 ml/min, the suggested dose is 70 mg piperacillin/8.75 mg tazobactam/kg every 8 hours
For adult and children 12 years and older patients on haemodialysis, one additional dose of piperacillin/tazobactam 2 g/0.25 g should be administered following each dialysis period, because haemodialysis removes 30–50% of piperacillin in 4 hours.
For children under the age of 12 years on haemodialysis, one additional dose of 40 mg piperacillin/5 mg tazobactam/kg should be administered following each dialysis period.
Hepatic impairment 

No dose adjustment is necessary.

Elderly patients

Patients over 65 years are not at an increased risk of developing adverse effects solely because of age. However, dosage should be adjusted in the presence of renal insufficiency.

Reference:Pfizer Malaysia Tazocin® EF Prescribing Information. Available at: https://labeling.pfizer.com/ShowLabeling.aspx?id=17746. Accessed on 15 July 2024.
Efficacy Learn more Loading
Product Information View Product Information Loading
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

This site is intended only for healthcare professionals residing in Malaysia. If you are a member of public wishing to access information on a specific medicine, please consult with your doctor.

 

This website is brought to you by
Pfizer (Malaysia) Sdn Bhd 197801003134
(40131-T)
Level 10 & 11, Wisma Averis (Tower 2),
Bangsar South, No. 8, Jalan Kerinchi, 
59200 Kuala Lumpur, Malaysia.
Tel: 603-2281 6000 
Fax: 603-2281 6388 
 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

PP-TAZ-MYS-0132-24JUL2024
You are now leaving the PfizerPro Malaysia website
You are now being directed to a third-party website. It is clarified that Pfizer will not be collecting, storing, or accessing any personal information shared by you on the third-party website and Pfizer's Privacy Policy will not apply. Pfizer does not review or control or endorse the content of the third-party website and shall have no liability / assumes no responsibility for any issues arising out of you accessing the third-party website, accuracy of the information, practices, and standards of the third-party website. You will be bound by the Privacy Policy and Terms of Use of the third-party website and be solely responsible for your interactions with that website.
 
     PP-UNP-MYS-0077 - 10FEB2023